Woodline Partners LP Sells 467,738 Shares of Immatics (NASDAQ:IMTX)

Woodline Partners LP reduced its position in shares of Immatics (NASDAQ:IMTX - Free Report) by 18.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,034,224 shares of the company's stock after selling 467,738 shares during the quarter. Woodline Partners LP owned about 1.70% of Immatics worth $14,463,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IMTX. Bank of America Corp DE boosted its holdings in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after purchasing an additional 2,231 shares during the period. Virtus ETF Advisers LLC boosted its holdings in shares of Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after purchasing an additional 2,479 shares during the period. Guggenheim Capital LLC purchased a new position in shares of Immatics in the 4th quarter worth approximately $101,000. Forefront Analytics LLC boosted its holdings in shares of Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after purchasing an additional 4,731 shares during the period. Finally, Graham Capital Management L.P. purchased a new position in shares of Immatics in the 4th quarter worth approximately $130,000. 64.41% of the stock is currently owned by institutional investors.

Immatics Stock Down 1.7%

IMTX traded down $0.09 during trading hours on Friday, reaching $5.11. 375,092 shares of the company's stock traded hands, compared to its average volume of 653,124. The firm has a 50-day moving average price of $4.52 and a 200 day moving average price of $5.70. Immatics has a 52-week low of $3.30 and a 52-week high of $13.77. The firm has a market capitalization of $621.12 million, a PE ratio of -7.74 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $20.12 million during the quarter, compared to analysts' expectations of $14.92 million. Equities analysts predict that Immatics will post -0.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IMTX shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st. Wall Street Zen cut Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $17.00.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.